NCT02667288已完成3 期
An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 147
- 试验地点
- 1
- 主要终点
- Proportion of Subjects With Lesion Clearance
研究概览
简要总结
This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.
详细描述
This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face. The Target Lesions will be treated a maximum of 4 times.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is at least 18 years of age
- •Clinical diagnosis of stable clinically typical seborrheic keratosis
- •Subject has 4 appropriate seborrheic keratosis Target Lesions on the trunk, extremities and face that each are eligible for treatment as defined below:
- •Have a clinically typical appearance
- •Have a PLA of 2 or greater and be a discrete lesion
- •Not be covered with hair which, in the investigator's opinion, would interfere with the study medication treatment or the study evaluations
- •Not be in an intertriginous fold
- •Not be on the eyelids
- •Not be within 5mm of the orbital rim
- •Not be pedunculated
- •If the subject is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an active method of birth control for the duration of the study
- •Subject is non-pregnant and non-lactating
- •Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair evaluation of any Target Lesion or which exposes the subject to an unacceptable risk by study participation
- •Subject is willing and able to follow all study instructions and to attend all study visits
- •Subject is able to comprehend and willing to sign an Informed Consent Form.
排除标准
- •Subject has clinically atypical and - or rapidly growing seborrheic keratosis lesions
- •Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of Lesser -Trelat)
- •Subject has a current systemic malignancy
- •Subject has used any of the following systemic therapies within the specified period prior to enrollment:
- •Retinoids; 180 days
- •Glucocortico-steroids;
- •Anti-metabolites (e.g., methotrexate);
- •Subject has used any of the following topical therapies within the specified period or in a proximity to any Target Lesion, that in the investigator's opinion interferes with the study medication treatment or the study assessments:
- •LASER, light or other energy based therapy (e.g., intense pulsed light, photo-dynamic therapy;
- •Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-flurouracil, or ingenol mebutate;
- •Retinoids;
- •Microdermabrasion or superficial chemical peels;
- •Glucocortico-steroids or antibiotics
- •Subject currently has or has had any of the following within the specified period or in a proximity to any Target Lesion that, in the investigator's opinion, interferes with the study medication treatment or the study assessments:
- •A cutaneous malignancy;
- •A sunburn; currently
- •A pre-malignancy (e.g., actinic keratosis); currently
- •Body art (e.g., tattoos, piercing, etc.); currently
- •Excessive tan; currently
- •Subject has a history of sensitivity to any of the ingredients in the study medications
- •Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations
- •Subject has participated in an investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to enrollment.
研究组 & 干预措施
A-101 Solution
Experimental
A-101 Solution 40% administered once
干预措施: A-101 Solution (Drug)
结局指标
主要结局
Proportion of Subjects With Lesion Clearance
时间窗: Study day 148
Proportion of subjects for whom all target lesions were judged to be clear on the Physician Lesion Assessment (PWA) Scale. The PWA scale is a 4 point scale used by the investigator to assess each subject target SK Lesion.
次要结局
- Per Subject Percent of Lesion Clearance(Day 148)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected SubjectsHIV InfectionNCT02154360University of Pennsylvania12
招募中
1 期
Phase I study of a Latanoprost Ocular Implant for treatment of Open Angle Glaucoma or Ocular Hypertension.Ocular HypertensionACTRN12621001718831PolyActiva Pty Ltd6
进行中（未招募）
不适用
A study to look at the effect of the study drug on heart muscle thickness, the amount of drug that ends up in the blood, and the safety and tolerability of study drug in Noonan syndrome patients.oonan syndrome hypertrophic cardiomyopathyMedDRA version: 14.1Level: PTClassification code 10029748Term: Noonan syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: PTClassification code 10020871Term: Hypertrophic cardiomyopathySystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-003392-10-GBovartis Pharma Services AG22
招募中
不适用
To investigate safety, tolerability and acceptability of needle free injection system in healthy volunteers in comparison to conventional needle-based system.CTRI/2021/01/030587IntegriMedical
进行中（未招募）
1 期
Study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia SyndromeFamilial Chylomicronemia SyndromeMedDRA version: 20.0Level: PTClassification code 10058108Term: DyslipidaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2018-002911-80-ITPRM|2121820